ArticleThe breast journal2026
Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL-2 in Breast Cancer.
Article in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL-2 in Breast Cancer.The breast journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBreast cancer is a leading female malignancy, with chronic inflammation driving progression. The IL-2/IL-2R axis regulates immunity, but IL2RA's role in breast cancer (expression, diagnostic/prognostic value, and interplay with IL-2) is unclear.
methodsA total of 252 consecutive patients (99 breast cancer and 153 benign breast disease) who received breast surgery were retrospectively analyzed. Serum cytokines were measured via electrochemiluminescence immunoassay; ROC, single-cell sequencing, and bioinformatics databases (TIMER and Kaplan-Meier plotter) were used to assess IL2RA/IL-2's utility and associations.
resultsSerum IL2Rα was higher in breast cancer (336.9 vs. 275.8 U/mL, p < 0.001; no significant differences were observed for other cytokines). IL2Rα showed moderate diagnostic performance (AUC = 0.650, cut-off = 240.5 U/mL), correlated with NLR (p = 0.012), and showed a trend towards poor survival (p = 0.124, HR = 0.309, 95% CI: 0.069-1.381). Single-cell sequencing identified T cells as the primary source of IL2Rα in tumor tissues. High IL2RA expression strongly correlated with infiltration of immune cells, especially neutrophils (r = 0.673) and dendritic cells (r = 0.706). RNA-seq analysis showed IL2RA was upregulated in tumor tissues, associated with poor prognosis (p = 9.7e - 06, HR = 1.29, 95% CI: 1.15-1.44) and aggressive features (e.g., lymph node metastasis and HER2 positivity). In contrast, IL-2 was highly expressed in normal tissues, linked to better prognosis (p = 0.001, HR = 0.83, 95% CI: 0.74-0.93), and had opposing clinical correlations.
conclusionsSerum IL2Rɑ could serve as a complementary auxiliary diagnostic biomarker for breast cancer, with associations with systemic inflammation, immune cell infiltration, and aggressive disease. The functional antagonism between IL2RA and IL-2 highlights the IL-2/IL2RA axis as a critical regulator of breast cancer pathophysiology, supporting its potential as a therapeutic target for improving breast cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.